2nd Quarter - Report
340B HEALTH for 340B HEALTH
Firm
Client
Income
—
Expenses
$273,761
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
The 340B Drug Pricing Program; FY 2021 L-HHS Appropriations; H.R. 3, Lower Drug Costs Now Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019; H.R. 5281, Drug Price Transparency in Medicaid Act of 2019; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; H.R.6201, Families First Coronavirus Response Act; H.R.748, CARES Act; HR 19, Lower Costs, More Cures Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELISE CRANSTON | — |
| KATHRYN DIBITETTO | — |
| GREG DOGGETT | — |
| KATE ILAHI | Legislative Assistant, Congressman Charlie Melancon (D-LA) |
| AMANDA SELLERS SMITH | — |
| MAUREEN TESTONI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.